Sat, May 18, 2013, 7:15 AM EDT - U.S. Markets closed
Byron Capital analyst Douglas Loe says the Alnylam study produced “the most dramatic “knockdown” data we have seen in clinical studies for a LNP-formulated SiRNA drug.” Full report:http://www.cantechletter.com/2012/07/byron-capital-analyst-douglas-loe-raises-target-on-tekmira-to-6-25/
The fact is this thing is STRUGGLING. Insiders can only keep the price up this high for sometime there WILL be a pullback and it will be significant.
agreed......this will fall and fall hard just like VRTX.....